SGMO: Summary for Sangamo Therapeutics, Inc. - Yahoo Finance

UK Markets close in 4 hrs 37 mins

Sangamo Therapeutics, Inc. (SGMO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.95-0.15 (-3.66%)
At close: 4:00PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous close4.10
Bid3.25 x 100
Ask4.10 x 500
Day's range3.77 - 4.15
52-week range2.65 - 7.60
Avg. volume983,685
Market cap278.96M
PE ratio (TTM)-3.66
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
Trade prices are not sourced from all markets
  • TheStreet.com7 days ago

    Biotech Premarket Movers: SGMO, IPXL, PTLA

    Sangamo Therapeutics, Impax Laboratories and Portola Pharmaceutical are among the premarket movers in biotech.

  • TheStreet.com9 days ago

    Biotech Premarket Movers: IPXL, SGMO, ARLZ

    Impax Laboratories, Sangamo Therapeutics and Aralez Pharmaceuticals are among the premarket movers in biotech.

  • PR Newswire9 days ago

    Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-318 Genome Editing Treatment for MPS I

    RICHMOND, Calif., Jan. 11, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO), the leader in therapeutic genome editing, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SB-318, a genome editing product candidate for the treatment of Mucopolysaccharidosis Type I (MPS I), a rare lysosomal storage disorder. Orphan drug designations are granted to drugs and biologics intended to treat rare diseases. Using Sangamo's zinc finger nuclease (ZFN) genome editing technology, SB-318 is designed as a single treatment strategy intended to provide stable, continuous production of the IDUA enzyme for the lifetime of the patient.